403 related articles for article (PubMed ID: 18827737)
1. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab.
Fintak DR; Shah GK; Blinder KJ; Regillo CD; Pollack J; Heier JS; Hollands H; Sharma S
Retina; 2008; 28(10):1395-9. PubMed ID: 18827737
[TBL] [Abstract][Full Text] [Related]
2. The article by Fintak et al on the incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab.
El-Ashry MF; Dhillon B
Retina; 2009 May; 29(5):720-1; author reply 721-2. PubMed ID: 19430287
[No Abstract] [Full Text] [Related]
3. Evaluation of safety for bilateral same-day intravitreal injections of antivascular endothelial growth factor therapy.
Lima LH; Zweifel SA; Engelbert M; Sorenson JA; Slakter JS; Cooney MJ; Klancnik JM; Yannuzzi LA; Freund KB
Retina; 2009 Oct; 29(9):1213-7. PubMed ID: 19934815
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor.
Inoue M; Kobayakawa S; Sotozono C; Komori H; Tanaka K; Suda Y; Matsushima H; Kinoshita S; Senoo T; Tochikubo T; Kadonosono K
Ophthalmologica; 2011; 226(3):145-50. PubMed ID: 21811052
[TBL] [Abstract][Full Text] [Related]
5. Histopathology of streptococcus mitis/oralis endophthalmitis after intravitreal injection with bevacizumab: a report of 7 patients.
Matthews JL; Dubovy SR; Goldberg RA; Flynn HW
Ophthalmology; 2014 Mar; 121(3):702-8. PubMed ID: 24439760
[TBL] [Abstract][Full Text] [Related]
6. We congratulate the authors for publishing their data on bilateral consecutive intravitreal injections administered in their office.
Shah GY; Ambatipudi S; Fernandes M; Lakshmipathy M; Varma PV; Sachdeva V; Pathengay A
Retina; 2010 Sep; 30(8):1325-6; author reply 1326-7. PubMed ID: 20827150
[No Abstract] [Full Text] [Related]
7. Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials.
Bhavsar AR; Googe JM; Stockdale CR; Bressler NM; Brucker AJ; Elman MJ; Glassman AR;
Arch Ophthalmol; 2009 Dec; 127(12):1581-3. PubMed ID: 20008710
[TBL] [Abstract][Full Text] [Related]
8. Incidence of Endophthalmitis after Intravitreal Anti-vascular Endothelial Growth Factor: Experience in Saudi Arabia.
Al-Rashaed S; Alsulaiman SM; Alrushood AA; Almasaud J; Arevalo JF
Middle East Afr J Ophthalmol; 2016; 23(1):60-3. PubMed ID: 26957840
[TBL] [Abstract][Full Text] [Related]
9. Endophthalmitis after intravitreal injection: the importance of viridans streptococci.
Chen E; Lin MY; Cox J; Brown DM
Retina; 2011 Sep; 31(8):1525-33. PubMed ID: 21878800
[TBL] [Abstract][Full Text] [Related]
10. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents.
Shah CP; Garg SJ; Vander JF; Brown GC; Kaiser RS; Haller JA;
Ophthalmology; 2011 Oct; 118(10):2028-34. PubMed ID: 21705087
[TBL] [Abstract][Full Text] [Related]
11. Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection.
Mason JO; White MF; Feist RM; Thomley ML; Albert MA; Persaud TO; Yunker JJ; Vail RS
Retina; 2008 Apr; 28(4):564-7. PubMed ID: 18398358
[TBL] [Abstract][Full Text] [Related]
12. An outbreak of streptococcus endophthalmitis after intravitreal injection of bevacizumab.
Goldberg RA; Flynn HW; Isom RF; Miller D; Gonzalez S
Am J Ophthalmol; 2012 Feb; 153(2):204-208.e1. PubMed ID: 22264943
[TBL] [Abstract][Full Text] [Related]
13. Postinjection Endophthalmitis Rates and Characteristics Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept.
Rayess N; Rahimy E; Storey P; Shah CP; Wolfe JD; Chen E; DeCroos FC; Garg SJ; Hsu J
Am J Ophthalmol; 2016 May; 165():88-93. PubMed ID: 26944277
[TBL] [Abstract][Full Text] [Related]
14. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting.
Pilli S; Kotsolis A; Spaide RF; Slakter J; Freund KB; Sorenson J; Klancnik J; Cooney M
Am J Ophthalmol; 2008 May; 145(5):879-82. PubMed ID: 18329624
[TBL] [Abstract][Full Text] [Related]
15. Incidence of endophthalmitis after intravitreal injection of antivascular endothelial growth factor medications using topical lidocaine gel anesthesia.
Inman ZD; Anderson NG
Retina; 2011 Apr; 31(4):669-72. PubMed ID: 21178659
[TBL] [Abstract][Full Text] [Related]
16. Comparison of endophthalmitis rates following intravitreal injection of compounded bevacizumab, ranibizumab, and aflibercept.
Forooghian F; Albiani DA; Kirker AW; Merkur AB
Can J Ophthalmol; 2017 Dec; 52(6):616-619. PubMed ID: 29217032
[TBL] [Abstract][Full Text] [Related]
17. Acute endophthalmitis after intravitreal injection and preventive effect of preoperative topical antibiotics.
Park Y; Kim KS; Park YH
J Ocul Pharmacol Ther; 2013 Dec; 29(10):900-5. PubMed ID: 24067061
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal injections at the Massachusetts Eye and Ear Infirmary: analysis of treatment indications and postinjection endophthalmitis rates.
Englander M; Chen TC; Paschalis EI; Miller JW; Kim IK
Br J Ophthalmol; 2013 Apr; 97(4):460-5. PubMed ID: 23390167
[TBL] [Abstract][Full Text] [Related]
19. Endophthalmitis after intravitreal vascular [corrected] endothelial growth factor antagonists: a six-year experience at a university referral center.
Moshfeghi AA; Rosenfeld PJ; Flynn HW; Schwartz SG; Davis JL; Murray TG; Smiddy WE; Berrocal AM; Dubovy SR; Lee WH; Albini TA; Lalwani GA; Kovach JL; Puliafito CA
Retina; 2011 Apr; 31(4):662-8. PubMed ID: 21836400
[TBL] [Abstract][Full Text] [Related]
20. Infectious and noninfectious endophthalmitis after intravitreal bevacizumab.
Jonas JB; Spandau UH; Rensch F; Von Baltz S; Schlichtenbrede F
J Ocul Pharmacol Ther; 2007 Jun; 23(3):240-2. PubMed ID: 17593007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
